skip to main content
Idioma:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Busca Simples
Refinado por: Nome da Publicação: Cancer remover assunto: Medical Sciences remover Female remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia
Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia
Material Type:
Artigo 		Adicionar ao Meu Espaço

Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia

Rizzieri, David A. ; O'Brien, Jenny A. ; Broadwater, Gloria ; Decastro, Carlos M. ; Dev, Prakash ; Diehl, Louis ; Beaven, Anne ; Lagoo, Anand ; Gockerman, Jon P. ; Chao, Nelson J. ; Moore, Joseph O.

Cancer, 2009-07, Vol.115 (13), p.2922-2929 [Periódico revisado por pares]

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Texto completo disponível

Citações Citado por
2
Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: Final results of cancer and leukemia group B study 9251
Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: Final results of cancer and leukemia group B study 9251
Material Type:
Artigo 		Adicionar ao Meu Espaço

Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: Final results of cancer and leukemia group B study 9251

RIZZIERI, David A ; JOHNSON, Jeffrey L ; CANELLOS, George P ; LARSON, Richard A ; NIEDZWIECKI, Donna ; LEE, Edward J ; VARDIMAN, James W ; POWELL, Bayard L ; BARCOS, Maurice ; BLOOMFIELD, Clara D ; SCHIFFER, Charles A ; PETERSON, Bruce A

Cancer, 2004-04, Vol.100 (7), p.1438-1448 [Periódico revisado por pares]

New York, NY: Wiley-Liss

Texto completo disponível

Citações Citado por
3
Low‐dose weekly paclitaxel for recurrent or refractory aggressive non‐Hodgkin lymphoma
Low‐dose weekly paclitaxel for recurrent or refractory aggressive non‐Hodgkin lymphoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Low‐dose weekly paclitaxel for recurrent or refractory aggressive non‐Hodgkin lymphoma

Rizzieri, David A. ; Sand, Gregory J. ; McGaughey, Dean ; Moore, Joseph O. ; DeCastro, Carlos ; Chao, Nelson J. ; Vredenburgh, James J. ; Gasparetto, Cristina ; Long, Gwynn D. ; Anderson, Elizabeth ; Foster, Tracy ; Toaso, Bonnie ; Adams, Donna ; Niedzwiecki, Donna ; Gockerman, Jon P.

Cancer, 2004-06, Vol.100 (11), p.2408-2414 [Periódico revisado por pares]

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Texto completo disponível

Citações Citado por
4
Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia
Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia
Material Type:
Artigo 		Adicionar ao Meu Espaço

Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia

Thomas, Deborah A. ; Faderl, Stefan ; O'Brien, Susan ; Bueso‐Ramos, Carlos ; Cortes, Jorge ; Garcia‐Manero, Guillermo ; Giles, Francis J. ; Verstovsek, Srdan ; Wierda, William G. ; Pierce, Sherry A. ; Shan, Jianqin ; Brandt, Mark ; Hagemeister, Fredrick B. ; Keating, Michael J. ; Cabanillas, Fernando ; Kantarjian, Hagop

Cancer, 2006-04, Vol.106 (7), p.1569-1580 [Periódico revisado por pares]

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Texto completo disponível

Citações Citado por
5
A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

Amato, Robert J. ; Jac, Jaroslaw ; Giessinger, Sarah ; Saxena, Somyata ; Willis, James P.

Cancer, 2009-06, Vol.115 (11), p.2438-2446 [Periódico revisado por pares]

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Texto completo disponível

Citações Citado por
6
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome‐related burkitt lymphoma/leukemia
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome‐related burkitt lymphoma/leukemia
Material Type:
Artigo 		Adicionar ao Meu Espaço

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome‐related burkitt lymphoma/leukemia

Cortes, Jorge ; Thomas, Deborah ; Rios, Adan ; Koller, Charles ; O'Brien, Susan ; Jeha, Sima ; Faderl, Stefan ; Kantarjian, Hagop

Cancer, 2002-03, Vol.94 (5), p.1492-1499 [Periódico revisado por pares]

New York: John Wiley & Sons, Inc

Texto completo disponível

Citações Citado por
7
New agents in acute myeloid leukemia and other myeloid disorders
New agents in acute myeloid leukemia and other myeloid disorders
Material Type:
Artigo 		Adicionar ao Meu Espaço

New agents in acute myeloid leukemia and other myeloid disorders

Ravandi, Farhad ; Kantarjian, Hagop ; Giles, Francis ; Cortes, Jorge

Cancer, 2004-02, Vol.100 (3), p.441-454 [Periódico revisado por pares]

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Texto completo disponível

Citações Citado por
8
Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma
Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma

Jimeno, Antonio ; Amador, María Luz ; González‐Cortijo, Lucía ; Tornamira, María Victoria ; Ropero, Santiago ; Valentín, Vicente ; Hornedo, Javier ; Cortés‐Funes, Hernán ; Colomer, Ramón

Cancer, 2004-05, Vol.100 (9), p.1833-1842 [Periódico revisado por pares]

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Texto completo disponível

Citações Citado por
9
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
Material Type:
Artigo 		Adicionar ao Meu Espaço

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

Kantarjian, Hagop ; Thomas, Deborah ; Jorgensen, Jeffrey ; Kebriaei, Partow ; Jabbour, Elias ; Rytting, Michael ; York, Sergernne ; Ravandi, Farhad ; Garris, Rebecca ; Kwari, Monica ; Faderl, Stefan ; Cortes, Jorge ; Champlin, Richard ; O'Brien, Susan

Cancer, 2013-08, Vol.119 (15), p.2728-2736 [Periódico revisado por pares]

Hoboken, NJ: Wiley-Blackwell

Texto completo disponível

Citações Citado por
10
Dose-Intensive Chemotherapy Including Rituximab in Burkitt's Leukemia or Lymphoma Regardless of Human Immunodeficiency Virus Infection Status: Final Results of a Phase 2 Study (Burkimab)
Dose-Intensive Chemotherapy Including Rituximab in Burkitt's Leukemia or Lymphoma Regardless of Human Immunodeficiency Virus Infection Status: Final Results of a Phase 2 Study (Burkimab)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Dose-Intensive Chemotherapy Including Rituximab in Burkitt's Leukemia or Lymphoma Regardless of Human Immunodeficiency Virus Infection Status: Final Results of a Phase 2 Study (Burkimab)

RIBERA, Josep-Maria ; GARCIA, Olga ; GARCIA, Daniel ; BRUNET, Salut ; ALONSO, Natalia ; BARBA, Pere ; MIRALLES, Pilar ; LLORENTE, Andreu ; MONTESINOS, Pau ; MORENO, Maria-José ; HERNANDEZ-RIVAS, Jose-Angel ; BERNAL, Teresa ; GRANDE, Carlos ; ESTEVE, Jordi ; ORIOL, Albert ; BERGUA, Juan ; GONZALEZ-CAMPOS, Jose ; VALL-ILOVERA, Ferran ; TORMO, Mar ; HERNANDEZ-RIVAS, Jesus-Maria

Cancer, 2013-05, Vol.119 (9), p.1660-1668 [Periódico revisado por pares]

Hoboken, NJ: Wiley-Blackwell

Texto completo disponível

Citações Citado por

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.